Teva Pharmaceuticals

(TASE, Nasdaq:

TEVA

) today announced two U.S. Food and Drug Administration approvals.

Teva says the FDA approved its ANDA - abbreviated new drug application - for Cefaclor extended release tablets, in dosages of 375 mg and 500 mg.

This is the first generic approval for the 375 mg strength, the Israeli drugmaker said.

TheStreet Recommends

It expects to begin shipping the product immediately.

The Cefaclor tablets are the AB-rated generic equivalent of Eli Lilly's Ceclor CD, marketed by the Ireland-based company Elan Corporation.

Cefaclor is a cephalosporin antibiotic with annual sales of $14 million, Teva said.

Earlier in the day, Teva announced final approval for

fenofibrate 67 milligram capsules

, used to treat excessive triglyceride levels in the blood.